Attorneys for a man suing AbbVie Inc., maker of AndroGel, told an Illinois federal jury that the drug company never tested its testosterone replacement therapy to rule out if it could cause heart problems, Law360 reported. Otherwise plaintiff Jeffrey Konrad would never have taken the drug, they said. Konrad’s case is the second bellwether trial in a multidistrict litigation (MDL) taking aim at testosterone manufacturers. AbbVie, as the maker of the top selling AndroGel, is the first drug maker to sit in the hot seat. The first trial against AbbVie ended in a $150 million in punitive damages for the ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.